Director
Syndax Pharmaceuticals
North Wales, Pennsylvania, United States
Dr. Enoch Cobbina is a drug development expert with a strong foundation in clinical pharmacology and pharmacometrics. His academic journey, marked by degrees in pharmacy, statistics, analytical chemistry, and a PhD in pharmaceutical sciences, equip him with a comprehensive understanding of the drug development lifecycle. Currently pursuing an MBA at Penn State, he is broadening his skill set to encompass strategic business acumen.
With a distinguished career spanning roles at Syndax Pharmaceuticals (Director), CSL Behring, Bristol Meyers Squibb, and Daiichi-Sankyo, Dr. Cobbina has solidified his position as a leader in the field. His expertise in model-informed drug development (MIDD) has been instrumental in advancing multiple therapeutic programs, from small molecules to complex biologics like monoclonal antibodies, antibody-drug conjugates, and gene therapy.
He is dedicated to enhancing value creation and organizational effectiveness in drug development through effective teamwork, innovative culture, and strong decision-making and communication. Dr. Cobbina advocates for these principles and mentors the next generation of pharmacometricians.
His contributions include several peer-reviewed articles, abstracts, and posters, with one of his review articles recognized as the best in the Drug Metabolism Review journal in 2017. Additionally, he serves as an adjunct associate professor at his alma mater’s College of Pharmacy.
Disclosure(s): No financial relationships to disclose
Building high performing teams to influence decisions in drug development.
Wednesday, November 13, 2024
12:15 PM – 1:45 PM MST
Wednesday, November 13, 2024
12:15 PM – 1:15 PM MST
